JP6486358B2 - （−）−（２ｒ，３ｓ）−２−アミノ−３−ヒドロキシ−３−ピリジン−４−イル−１−ピロリジン−１−イル−プロパン−１−オン・（ｌ）−（＋）酒石酸塩、その製造方法及び使用 - Google Patents

（−）−（２ｒ，３ｓ）−２−アミノ−３−ヒドロキシ−３−ピリジン−４−イル−１−ピロリジン−１−イル−プロパン−１−オン・（ｌ）−（＋）酒石酸塩、その製造方法及び使用 Download PDF

Info

Publication number
JP6486358B2
JP6486358B2 JP2016534827A JP2016534827A JP6486358B2 JP 6486358 B2 JP6486358 B2 JP 6486358B2 JP 2016534827 A JP2016534827 A JP 2016534827A JP 2016534827 A JP2016534827 A JP 2016534827A JP 6486358 B2 JP6486358 B2 JP 6486358B2
Authority
JP
Japan
Prior art keywords
hydroxy
amino
pyridin
tartrate
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016534827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016528255A5 (https=
JP2016528255A (ja
Inventor
ジェルジュ エフ アンブラス
ジェルジュ エフ アンブラス
キャサリン シー クルジャン
キャサリン シー クルジャン
ジャコポ ザノン
ジャコポ ザノン
ジョヴァンナ リブラロン
ジョヴァンナ リブラロン
ファヴェーリ カールラ デ
ファヴェーリ カールラ デ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2016528255A publication Critical patent/JP2016528255A/ja
Publication of JP2016528255A5 publication Critical patent/JP2016528255A5/ja
Application granted granted Critical
Publication of JP6486358B2 publication Critical patent/JP6486358B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2016534827A 2013-08-15 2014-08-14 （−）−（２ｒ，３ｓ）−２−アミノ−３−ヒドロキシ−３−ピリジン−４−イル−１−ピロリジン−１−イル−プロパン−１−オン・（ｌ）−（＋）酒石酸塩、その製造方法及び使用 Active JP6486358B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361866155P 2013-08-15 2013-08-15
US61/866,155 2013-08-15
PCT/US2014/051007 WO2015023816A1 (en) 2013-08-15 2014-08-14 (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use

Publications (3)

Publication Number Publication Date
JP2016528255A JP2016528255A (ja) 2016-09-15
JP2016528255A5 JP2016528255A5 (https=) 2017-09-21
JP6486358B2 true JP6486358B2 (ja) 2019-03-20

Family

ID=51398940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016534827A Active JP6486358B2 (ja) 2013-08-15 2014-08-14 （−）−（２ｒ，３ｓ）−２−アミノ−３−ヒドロキシ−３−ピリジン−４−イル−１−ピロリジン−１−イル−プロパン−１−オン・（ｌ）−（＋）酒石酸塩、その製造方法及び使用

Country Status (13)

Country Link
US (2) US9242935B2 (https=)
EP (2) EP3033327B1 (https=)
JP (1) JP6486358B2 (https=)
CN (2) CN108794386B (https=)
CA (1) CA2921385C (https=)
DK (1) DK3033327T3 (https=)
ES (1) ES2664749T3 (https=)
HU (1) HUE036381T2 (https=)
NO (1) NO2960430T3 (https=)
PL (1) PL3033327T3 (https=)
PT (1) PT3033327T (https=)
SI (1) SI3033327T1 (https=)
WO (1) WO2015023816A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2921385C (en) 2013-08-15 2021-10-19 Allergan, Inc. (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use
US9992703B2 (en) * 2016-04-04 2018-06-05 Cisco Technology, Inc. Insertion of management packet into a deterministic track
US20250161264A1 (en) * 2022-02-11 2025-05-22 Gilgamesh Pharmaceuticals, Inc. (ampar-pam)-nmda receptor antagonist combination therapy for treatment of mental conditions and disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545745A (en) * 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
AU2002348261A1 (en) * 2001-11-26 2003-06-10 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US20090088433A1 (en) * 2005-01-26 2009-04-02 Bertrand Leblond Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008011483A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
WO2008011478A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
JP2010520299A (ja) * 2007-03-06 2010-06-10 アラーガン、インコーポレイテッド ３−アリール−３−ヒドロキシ−２−アミノ−プロピオン酸アミド、３−ヘテロアリール−３−ヒドロキシ−２−アミノ−プロピオン酸アミドおよび関連化合物を使用する認知障害の処置方法
US8173683B2 (en) * 2007-03-06 2012-05-08 Allergan, Inc. Methods for treating cognitive disorders
WO2008109286A1 (en) * 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds
CA2921385C (en) 2013-08-15 2021-10-19 Allergan, Inc. (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use

Also Published As

Publication number Publication date
CA2921385C (en) 2021-10-19
CN108794386B (zh) 2021-06-22
EP3033327B1 (en) 2018-01-03
US20150051253A1 (en) 2015-02-19
CN105555765A (zh) 2016-05-04
EP3033327A1 (en) 2016-06-22
CN108794386A (zh) 2018-11-13
ES2664749T3 (es) 2018-04-23
NO2960430T3 (https=) 2018-01-06
US9540328B2 (en) 2017-01-10
US9242935B2 (en) 2016-01-26
SI3033327T1 (en) 2018-05-31
JP2016528255A (ja) 2016-09-15
HK1224292A1 (zh) 2017-08-18
CN105555765B (zh) 2018-05-25
CA2921385A1 (en) 2015-02-19
HUE036381T2 (hu) 2018-07-30
EP3336079A1 (en) 2018-06-20
DK3033327T3 (en) 2018-04-16
PT3033327T (pt) 2018-04-04
US20160347712A1 (en) 2016-12-01
WO2015023816A1 (en) 2015-02-19
PL3033327T3 (pl) 2018-07-31

Similar Documents

Publication Publication Date Title
AU2014239995B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
IL174942A (en) Derivatives of n-[phenyl(piperidine-2-yl)methyl]arylamides, pharmaceutical compositions comprising them and their use in the preparation of medicaments
TW202106680A (zh) Glyt1抑制劑之固體形式
JP2022513030A (ja) ヒストン脱アセチル化酵素６阻害剤を含む薬学的組成物
TW201408656A (zh) 胺基甲酸酯／尿素衍生物
CN114206859B (zh) 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途
JP6486358B2 (ja) （−）−（２ｒ，３ｓ）−２−アミノ−３−ヒドロキシ−３−ピリジン−４−イル−１−ピロリジン−１−イル−プロパン−１−オン・（ｌ）−（＋）酒石酸塩、その製造方法及び使用
TWI462915B (zh) 一種組織胺ｈ３受體拮抗劑的新穎富馬酸鹽
US20110306633A1 (en) Selective m4 receptor antagonist and its medical use
KR20230148177A (ko) N-((r)-2,3-디하이드록시프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤즈아미드의 본질적으로 순수한 형태 iv의 조성물 및 이의 용도
JP5888612B2 (ja) 縮合ピリジン化合物塩の結晶
HK40000407B (zh) 包含单酒石酸盐的药物组合物及其用途
JP7194828B2 (ja) コリダルミンの結晶性塩
HK40000407A (en) A pharmaceutical composition comprising a monotartrate salt and use thereof
HK1224292B (en) (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use
JP2005519036A (ja) 治療用化合物のクエン酸塩及びその医薬組成物
JP6078153B2 (ja) チアンジンアミド誘導体、並びにその医薬組成物及び使用
JPWO2004080965A1 (ja) ニューロペプチドｆｆ受容体拮抗剤
JPH10503214A (ja) アミノメチル アリール化合物；ドーパミンレセプター亜型選択性リガンド
KR102900330B1 (ko) 이중 억제제 화합물 및 이들의 의약 용도
WO2023225601A2 (en) Ripk2 and nod inhibitors
KR100786315B1 (ko) 페닐에탄올아미노테트랄린카르복실산아미드유도체
WO2017120532A1 (en) Polymorphs of a phosphate salt of quinuclidin-4-ylmethyl 4-methyl-1h-indole-3-carboxylate and uses thereof
EA050218B1 (ru) Производные 6-метилурацила, обладающие антихолинэстеразной активностью, и их применение
HK40062278A (en) Crystalline forms of (s)-2-(7-cyano-1h-benzimidazol-1 yl)- n-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180423

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190219

R150 Certificate of patent or registration of utility model

Ref document number: 6486358

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250